Trials / Completed
CompletedNCT01001481
Schizophrenia Treatment Adherence Investigation (STAI)
Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 550 (actual)
- Sponsor
- Janssen-Cilag Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.
Detailed description
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Risk status for medication adherence | Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-10-26
- Last updated
- 2014-04-09
Source: ClinicalTrials.gov record NCT01001481. Inclusion in this directory is not an endorsement.